Lineage Cell Therapeutics, Inc. (LCTX.TA)
LCTX.TA Stock Price Chart
Explore Lineage Cell Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze LCTX.TA price movements and trends.
LCTX.TA Company Profile
Discover essential business fundamentals and corporate details for Lineage Cell Therapeutics, Inc. (LCTX.TA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Sept 2015
Employees
70.00
Website
https://lineagecell.comCEO
Brian M. Culley
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX.TA Financial Timeline
Browse a chronological timeline of Lineage Cell Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 13 Nov 2025
Revenue estimate is ILA 2.30M.
Earnings released on 12 Aug 2025
EPS came in at -ILA 0.45 falling short of the estimated -ILA 0.09 by -395.09%, while revenue for the quarter reached ILA 9.25M , beating expectations by +389.96%.
Earnings released on 13 May 2025
EPS came in at -ILA 0.07 surpassing the estimated -ILA 0.10 by +28.51%, while revenue for the quarter reached ILA 5.62M , beating expectations by +225.89%.
Earnings released on 10 Mar 2025
EPS came in at -ILA 0.06 surpassing the estimated -ILA 0.11 by +42.35%, while revenue for the quarter reached ILA 10.43M , beating expectations by +666.08%.
Earnings released on 15 Nov 2024
EPS came in at -ILA 0.06 surpassing the estimated -ILA 0.15 by +59.24%, while revenue for the quarter reached ILA 14.31M , beating expectations by +782.62%.
Earnings released on 9 Aug 2024
EPS came in at -ILA 0.11 surpassing the estimated -ILA 0.17 by +32.44%, while revenue for the quarter reached ILA 5.30M , beating expectations by +48.76%.
Earnings released on 10 May 2024
EPS came in at -ILA 0.13 surpassing the estimated -ILA 0.14 by +6.95%, while revenue for the quarter reached ILA 5.32M , beating expectations by +5.93%.
Earnings released on 8 Mar 2024
EPS came in at -ILA 0.10 surpassing the estimated -ILA 0.16 by +36.88%, while revenue for the quarter reached ILA 7.52M , missing expectations by -21.69%.
Earnings released on 10 Nov 2023
EPS came in at -ILA 0.16 surpassing the estimated -ILA 0.16 by +2.17%, while revenue for the quarter reached ILA 4.77M , missing expectations by -51.92%.
Earnings released on 11 Aug 2023
EPS came in at -ILA 0.11 surpassing the estimated -ILA 0.16 by +31.41%, while revenue for the quarter reached ILA 11.87M , beating expectations by +45.49%.
Earnings released on 12 May 2023
EPS came in at -ILA 0.09 surpassing the estimated -ILA 0.14 by +32.84%, while revenue for the quarter reached ILA 8.54M , beating expectations by +7.46%.
Earnings released on 9 Mar 2023
EPS came in at -ILA 0.03 falling short of the estimated -ILA 0.03 by -19.24%, while revenue for the quarter reached ILA 6.60M , missing expectations by -26.88%.
Earnings released on 10 Nov 2022
EPS came in at -ILA 0.04 falling short of the estimated -ILA 0.04 by -14.29%, while revenue for the quarter reached ILA 10.60M , missing expectations by -23.63%.
Earnings released on 11 Aug 2022
EPS came in at -ILA 0.04 falling short of the estimated -ILA 0.04 by -6.67%, while revenue for the quarter reached ILA 15.85M , beating expectations by +23.04%.
Earnings released on 12 May 2022
EPS came in at -ILA 0.04 falling short of the estimated -ILA 0.03 by -17.65%, while revenue for the quarter reached ILA 16.72M , missing expectations by -28.63%.
Earnings released on 10 Mar 2022
EPS came in at -ILA 0.17 falling short of the estimated -ILA 0.05 by -240.00%, while revenue for the quarter reached ILA 2.98M , beating expectations by +14.20%.
Earnings released on 10 Nov 2021
EPS came in at -ILA 0.05 matching the estimated -ILA 0.05, while revenue for the quarter reached ILA 7.09M .
Earnings released on 12 Aug 2021
EPS came in at -ILA 0.03 falling short of the estimated -ILA 0.03 by -18.20%, while revenue for the quarter reached ILA 1.44M .
Earnings released on 13 May 2021
EPS came in at -ILA 0.01 falling short of the estimated -ILA 0.01 by -71.53%, while revenue for the quarter reached ILA 975.43K .
Earnings released on 11 Mar 2021
EPS came in at ILA 0.01 surpassing the estimated -ILA 0.05 by +120.00%, while revenue for the quarter reached ILA 533.32K .
Earnings released on 4 Nov 2020
EPS came in at -ILA 0.05 falling short of the estimated -ILA 0.05 by -11.11%, while revenue for the quarter reached ILA 1.17M .
LCTX.TA Stock Performance
Access detailed LCTX.TA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.